The oncology precision medicine industry is rapidly evolving as cutting-edge technologies increasingly enable personalized cancer treatments tailored to patients’ genetic profiles. Fueled by innovations in genomics and bioinformatics, this sector is witnessing significant advances in targeted therapies, driving transformative outcomes in oncology care and reshaping treatment paradigms globally.


Market Size and Overview
The Global Oncology Precision Medicine Market is estimated to be valued at USD 153.81 billion in 2025 and is expected to reach USD 281.17 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.00% from 2025 to 2032.

This remarkable Oncology Precision Medicine Market Growth reflects expanding investments in novel precision therapies and biomarker-driven diagnostics. The increasing adoption of next-generation sequencing and integration of artificial intelligence in oncology drug development further contribute to the growing market scope and dynamics.

Market Segments

The Oncology Precision Medicine Market is primarily segmented by product type, application, and end-user. Under product type, targeted therapies dominate with a rapidly growing sub-segment of immunotherapies, exemplified by the approval of novel CAR-T treatments between 2024 and 2025. In terms of application, solid tumor treatments remain the largest category, while liquid biopsy applications are the fastest-growing sub-segment, supported by increased clinical adoption reported in 2025.

End-users include hospitals, specialized cancer centers, and research institutes, among which cancer specialty hospitals show accelerated revenue growth due to increased patient throughput and precision-guided protocols.

‣ Get more insights on : Oncology Precision Medicine Market

‣ Get this Report in Japanese Language: 腫瘍学の精密医療市場

‣ Get this Report in Korean Language:   종양학정밀의학시장